Featured Research

from universities, journals, and other organizations

Bone drug zoledronic acid may help prevent spread of early lung cancer

Date:
February 26, 2011
Source:
European Society for Medical Oncology
Summary:
A drug that is currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier stage of treatment, to prevent the cancer from spreading in the first place, researchers have found.

A drug that is currently used to help treat bone metastases in patients with lung cancer could also be useful at an earlier stage of treatment, to prevent the cancer from spreading in the first place, Italian researchers have found.

Related Articles


Dr Michela Quirino and colleagues from the Catholic University of the Sacred Heart in Rome have reported important new evidence that zoledronic acid may be able to prevent lung cancer metastases from recruiting the new blood vessels they need to survive. This process of recruiting new blood vessels is called angiogenesis.

"Our investigation represents the first clear clinical evidence of the anti-angiogenic effect of zoledronic acid in patients with metastatic lung cancer," Dr Quirino said. "It also represents the first biological basis in lung cancer for the clinical investigation of zoledronic acid not only for metastatic lung cancer, but also in early disease."

Dr Quirino presented findings from a study of 41 patients with advanced lung cancer.

Each patient was administered 4 mg of zoledronic acid, and their blood levels of several molecular markers of angiogenesis were measured before and 48 hours after the injection. Those markers included the molecules VEGF, PDGF, b-FGF and HGF.

"We found a statistically significant reduction of VEGF levels at day 2 after 4 mg ZA intravenous infusion compared with basal values," Dr Quirino said. Blood levels of bFGF were also significantly reduced. "Some studies reported that VEGF secretion is induced by bFGF and this could support our results," she added.

The researchers did not record any significant effect of injecting the drug on the levels of the other two mediators of angiogenesis, PDGF and HGF.

Treatment with zoledronic acid is already an important treatment to manage bone metastases from lung cancer, Dr Quirino noted. Some clinical studies have already demonstrated that zoledronic acid in bone metastases from lung cancer improves clinical outcomes and patient survival.

"If further studies should confirm a possible anti-metastatic effect of this drug, possibly relying also on its anti-angiogenic effect, it could be introduced in the early management of the disease, even as an adjuvant therapy."

Commenting on the study, which he was not involved in, Prof Ken O'Byrne, from St James's Hospital in Dublin, Ireland, said: "These observations underline the importance of targeting VEGF in non-small cell lung cancer and the potential role bFGF may have in tumor growth and metastasis. The results lay the groundwork for evaluating the potential role of zoledronic acid in the treatment of lung cancer independently of the effects on bone metastases."


Story Source:

The above story is based on materials provided by European Society for Medical Oncology. Note: Materials may be edited for content and length.


Cite This Page:

European Society for Medical Oncology. "Bone drug zoledronic acid may help prevent spread of early lung cancer." ScienceDaily. ScienceDaily, 26 February 2011. <www.sciencedaily.com/releases/2011/02/110225082926.htm>.
European Society for Medical Oncology. (2011, February 26). Bone drug zoledronic acid may help prevent spread of early lung cancer. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2011/02/110225082926.htm
European Society for Medical Oncology. "Bone drug zoledronic acid may help prevent spread of early lung cancer." ScienceDaily. www.sciencedaily.com/releases/2011/02/110225082926.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins